Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma
O'Sullivan, C.C.; Ozdemirli, M.; Bazylewicz, M.; Cheson, B.D.
Clinical Advances in Hematology and Oncology H&o 11(6): 382-385
2013
ISSN/ISBN: 1543-0790 PMID: 24472809 Document Number: 666808
Document emailed within 1 workday
Related Documents
2014: Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant Clinical Advances in Hematology and Oncology: H&o 12(8 Suppl. 16): 20Al-Mansour, M.; Al-Maghraby, H.; Shirah, B. 2020: Transformation of Grade i Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD30+ ALK1- with Complete Response to Brentuximab Vedotin and High-Dose Methotrexate Gulf Journal of Oncology 1(33): 87-90
Siddiqui, N.; Al-Diab, A.I. 2005: Nodular lymphocyte predominant Hodgkin's lymphoma Saudi Medical Journal 26(2): 241-245
Cao, Z.G.; Wang, Z.H.; Sun, J.Z.; Liu, M.; Zhou, X.Y.; Yang, Q.M. 2016: A case report of refractory ALK-positive anaplastic large cell lymphoma treated with Brentuximab vedotin Zhonghua Zhong Liu Za Zhi 38(9): 715-716
Rysenga, E.; Linden, M.D.; Carey, J.L.; Ross, C.W.; Schnitzer, B.; Sawdyk, M.; Maeda, K. 1995: Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease Archives of Pathology and Laboratory Medicine 119(1): 88-91
Marafioti, T.; Mancini, C.; Ascani, S.; Sabattini, E.; Zinzani, P.Luigi.; Pozzobon, M.; Pulford, K.; Falini, B.; Jaffe, E.S.; Müller-Hermelink, H-Konrad.; Mason, D.Y.; Pileri, S.A. 2004: Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease Haematologica 89(8): 957-964
Kositwattanarerk, A.; Changmuang, W.; Sangsuriyan, J.; Thongklam, K.; Sritara, C.; Utamakul, C.; Chamroonrat, W.; Thamnirat, K.; Anongpornyochkul, Y.; Chancharunee, S. 2013: 131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: the first case report in Thailand Journal of the Medical Association of Thailand 96(6): 756-760
Sarris, A.H.; Romaguera, J.; Hagemeister, F.B.; Rodriguez, M.A.; McLaughlin, P.; Pro, B.; Younes, A.; Mesina, O.; Cabanillas, F.; Medeiros, L.J.; Samuels, B. 2001: Irinotecan in relapsed or refractory non-Hodgkin's lymphoma Oncology 15(7 Suppl. 8): 53-56
Davidson, K.L.; Devaney, M.B.; Tighe, J.E.; Rogers, S.Y.; Dunlop, D.J.; Mackie, M.J.; Thomas, R.V.; Johnson, P.R.E. 2003: A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study Haematologica 88(12): 1366-1371
Stiff, P.J. 1998: Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma Oncology 12(10 Suppl 8: 56-62
Nishimori, H.; Fujii, N.; Maeda, Y.; Matsuoka, K.-I.; Takenaka, K.; Shinagawa, K.; Ikeda, K.; Matsuo, K.; Harada, M.; Tanimoto, M. 2009: Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma Anticancer Research 29(5): 1749-1754
Rudders, R.A.; Hensleigh, D. 1975: Prognosis of diffuse (non-nodular) non-Hodgkin's lymphoma Cancer ChemoTherapy Reports 59(2 Part 1): 421-424
Herold, M.; Sacchi, S.; Hieke, K. 2002: The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use Haematologica 87(7): 719
Nakata, W.; Tokuyama, N.; Yagioka, H.; Suyama, Y.; Ogura, K. 2016: Complete Response in a Patient with HER2-Positive Gastric Cancer and Multiple Lung Metastases with Trastuzumab-Containing Chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(5): 625-627
Zinzani, P.L.; Martelli, M.; Tura, S.; Mandelli, F. 1993: Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma Haematologica 78(1): 40-43
Matsue, K.; Harada, M.; Shiobara, S.; Okada, K.; Kondo, K.; Ueda, M.; Nakao, S.; Misawa, T.; Ohtake, S.; Hattori, K. 1983: Inhibition of donor's mixed lymphocyte culture and phytohemagglutinin response by chimeric mononuclear cells of an allogenic marrow transplant patient Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 46(3): 767-771
Riera, L.; Koziner, B. 2000: Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells Medicina 60(2): 259-269
Montalban, C.; Bellas, C.; Rodriguez-Garcia, J.L.; Aguado, M.; Fernandez-Muñoz, R. 1991: Non-Hodgkin's lymphoma after prolonged remission of Hodgkin's disease in an HIV-infected patient Annals of Oncology: Official Journal of the European Society for Medical Oncology 2(8): 585-587
Bucerius, J.; Herkel, C.; Joe, A.Y.; Altehoefer, C.; Finke, J.; Moser, E.; Reinhardt, M.J. 2006: (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies Nuklearmedizin. Nuclear medicine 45(3): 105-10; quiz N25-6
Biggs, D.; Stadtmauer, E.; Mangan, P.; Edelstein, M.; Powlis, W.; Buzby, G.; Magee, D.; Sachs, B.; Silberstein, L. 1994: 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery Progress in Clinical and Biological Research 389: 9-15